+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

Visiongain Publishes Varicose Veins Treatment Devices Market Forecast 2020-2030

27 September 2020

Varicose Veins Treatment Devices Market Forecast 2020-2030: Forecasts and Analysis By Type, and Geography, with Profiles of Leading Companies, with Profiles of Leading Companies report provides impartial Varicose Veins Treatment Devices sector analysis.

According to the report published by Visiongain, the Varicose Veins Treatment Devices market was valued at approximately USD xx billion in 2019 and is expected to grow at a CAGR of around xx% between 2020 and 2030. The venous network of the lower limbs is split into two primary systems: the vein deep and the venous system superficial. Both systems have a perforator vein connection. The deep vein system comprises the popliteal and femoral veins; the superficial vein system comprises the large saphenous and small, saphenous veins. In the upper thigh, the GSV is usually 3 to 4 mm in diameter, while the GSV meets the saphenophemoral crossing (SFJ). Roughly 60 percent of varicosity patients had GSV reflux.

Varicose Veins Treatment Devices Market is witnessing Growth due to factors such as
The narrow saphenous vein does not normally have a diameter of less than 3 mm and joins to the deep veins at the SPJ in the knee area. Typically, the failure of valves at SFJ and SPJ causes the incompetence of the surface venous system with a resulting pressure that is worse at the more distal area of the vein. Thanks to the calf pump process, weakness of the perforating veins often results in increased stress in the superficial venous network. Varices are veins which empty into a wider vein. For average, the width of varicose veins is between 3–10 mm. Inadequate emptying of the vein (i.e. venous insufficiency) has been associated with varicose veins in the lower extremity and includes pain, cramping and dolence, burning, throbbing, swelling, and feeling of loudness or fatigue in the leg. In fact, standing and warm weather worsen effects.

The ultimate outcome of saphenous varicose veins are insoluble ulcerations and repeated bleeding. The thrombophlebitis and other complications of patients with greater varicosities (e.g., varicose veins with a diameter greater than 3 mm) are more prone than those with smaller varicosities. Varicosities may also be associated with chronic cellulitis. Telangiectases are blood vessels that are permanently diluted, also called spider veins, creating fine red or blue skin lines. The varicose veins are similar but limited to dermis and usually have not more than 3 mm of diameter. They are generally not associated with symptoms and treatment is not medicinally necessary but usually considered cosmetic. During pregnancy, varicose veins may develop.

Treatment is not necessary as most varicosities can cure spontaneously within 4-6 months. The upper extremity veins of varicose veins are rare and few reports of upper extremity varicosity management are published in the medical literature reviewed by the pairs. However, authors have reported successful results using lower extremity-like treatment methods.

Different technology for the physiological characteristics of varicosities are used in conjunction with other non-invasive testing, given that physical examinations alone cannot be reliable. Ultra varicose veins may All be used to diagnose varicose veins with duplex, Doppler and plethysmography. In most cases, it is not essential to have a follow-up scan for subsequent sclerotherapy sessions when the initial vein mapping is performed. Repeating duplex or doppler studies, as part of sclerotherapy sequences, have not been demonstrated in published medical literature for the effective conclusion of the procedure. Also, routine use of any of these tools in the absence of venous symptoms or clinical evidence of venous insufficiency or reflux is not considered a medical necessity. Photographs or diagrams are helpful in assessing the size and extent of the varicosities

Shift in Trends
Sclerotherapy is a noninvasive method involving the injection of a sclerosing foam into the veins. It does not require vein slicing. It is less intense. Patient recovery is faster because hospital admission is not required. Medicare also offers coverage of sclerotherapy-treated patients in the U.S. In addition. In 2019, in the United States, there were more than 375,000 sclerotherapy procedures. In the coming years, insurance coverage can increase sclerotherapy.

Due to different advantages such as less bruising, less scars, no necessity of sedation and a need for long-term hospitalization, simple follow-up treatment, and positive reimbursement policies, the sclerosis segment accounted for the highest market share in 2018. STS has innovative treatment and long-term success in the use of foam STS in sclerotherapy.

Annual efforts to raise awareness and encourage the adoption of different treatments are undertaken by several organizations, including the United Kingdom Association of Sculpture Therapies (BAS). More and more permits are also continuing to expand the sector. Data on the VenaSeal System pre-market approval were reviewed in February 2015 by the Food and Drug Administration (FDA). The FDA approval system for VenaSeal involved evaluating the outcomes of three clinical trials. Medtronic said new CPT codes might help to secure positive coverage by public and private insurers for its VenaSeal closure device in November 2017 in the United States.

Over the forecast period, the endovenous ablation market is anticipated to be the fastest growing. By contrast with traditional methods such as functional stripping and ligation, the endovenous ablation process is superior, as the treatment is minimally invasive and less complex. In addition, different market players are focusing on developing efficient and high-tech products that are likely to boost market growth.

Regional Market Analysis
Throughout 2019, North America dominated the revenue share segment, because it has an esthetically oriented large population base. Because of the obvious results and safety, people are willing to follow cosmetic procedure. Early adoption in North America, laser treatment safety and effectiveness demonstrations contributed to a reduction in the stigma associated with cosmetic processes and to the social acceptance of laser treatments in particular in men. Advanced technology also stimulates the market growth of varicose vein treatment equipment. In May 2016, Navegara established a vein center in the U.S. to educate the community on chronic vein and varicose vein insufficiency and proper treatment. About 30 million Americans are varicose vein victims every year and are receiving treatment less than 10% of the population.

Together with the American Venous Forum, the Society for Vascular Surgery has developed a guideline for the treatment of varicose veins. These guidelines provide recommendations for managing grade system-based chronic vein diseases. The degree to which the condition is severe helps insurers communicate with each other. For example, a general practitioner can effectively communicate the severity by referring patients to vein specialists. Patients can be categorized according to severity into different groups. These guidelines recommend chronic vein diseases in the system of grade. Insurers communicate with each other to the degree to which their situation is severe. For example, a practitioner can communicate seriousness effectively by referring patients to vein specialists. Patients can be divided into different groups according to their severity.

Competition in the market
The main players in the market include AngioDynamics, Inc.; Medtronic, Syneron Medical Ltd.; Biolitec, Inc.; Lumenis Ltd.; The Energist Group; Eufoton, S.p. S.; and Quanta Systems, Inc. Medtronic, followed by Teleflex, Inc. was the leading revenue company. These companies ' higher revenue growth is attributable to the broad product portfolio, increased global penetration as well as various strategic initiatives. Medtronic, for instance, created and provided the U.S. VenaSeal Closure Program. In February 2015 FDA approval and 2017 insurance cover. Therefore, the development, marketing and availability of product reimbursements are some of the main strategies that market players have adopted to maintain their dominance.

In February 2017, Teleflex bought around USD 1 billion from Vascular Solutions, Inc. This purchase was planned by providing additional sales relevant to the peripheral and coronary Vascular Solutions sector to improve the Vascular and Intervention services portfolios of the former. In addition, the purchase of products directly from their respective companies to be sold as a distributor is a key strategic strategy put in place by some market players. In 2006, for instance, Sotradecol was purchased from Bioniche Pharma Group Limited by AngioDynamics Inc. and in March 2016 from Asclera.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2024-2034

The global Pharma Wholesale and Distribution market is estimated at US$844.2 billion in 2024 and is projected to grow at a CAGR of 8.7% during the forecast period 2024-2034.

20 February 2024


Visiongain Publishes Biobanking Market Report 2024-2034

The global Biobanking market is estimated at US$75.4 billion in 2024 and is projected to grow at a CAGR of 9.1% during the forecast period 2024-2034.

19 February 2024


Visiongain Publishes Dermatological Drugs Market Report 2024-2034

The Dermatological Drugs market is estimated at US$30.47 billion in 2024 and is projected to grow at a CAGR of 10.5% during the forecast period 2024-2034.

13 February 2024


Visiongain Publishes Allergic Rhinitis Drugs Market Report 2024-2034

The global Allergic Rhinitis Drugs market is estimated at US$16,821.6 million in 2024 and is expected to register a CAGR of 2.7% from 2024 to 2034.

12 February 2024